Dr Pourhassan says Dr Sacha, who has not been given an equity stake in the company, will lead the development of the company’s flagship leronlimab (PRO 140) drug as a potential therapy for HIV pre-exposure prophylaxis (PrEP) and cure for HIV.
CytoDyn brings on senior science advisor to develop leronlimab to treat HIV PrEP
Quick facts: CytoDyn
Market Cap: $156.77 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE